Head-To-Head Contrast: ATS (NYSE:ATS) vs. Wuhan General Group (OTCMKTS:WUHN)

ATS (NYSE:ATS) and Wuhan General Group (OTCMKTS:WUHN) are both industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Volatility & Risk

ATS has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Wuhan General Group has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ATS and Wuhan General Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ATS	1	2	2	0	2.20
Wuhan General Group	0	0	0	0	0.00

ATS currently has a consensus price target of $35.00, suggesting a potential upside of 8.04%. Given ATS’s stronger consensus rating and higher possible upside, research analysts plainly believe ATS is more favorable than Wuhan General Group.

Valuation & Earnings

This table compares ATS and Wuhan General Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ATS	$1.82 billion	1.75	-$20.16 million	$0.15	215.97
Wuhan General Group	N/A	N/A	N/A	N/A	N/A

Wuhan General Group has lower revenue, but higher earnings than ATS.

Institutional and Insider Ownership

75.8% of ATS shares are held by institutional investors. 61.1% of Wuhan General Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ATS and Wuhan General Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ATS	0.77%	9.67%	3.74%
Wuhan General Group	N/A	N/A	N/A

Summary

ATS beats Wuhan General Group on 9 of the 10 factors compared between the two stocks.

About ATS

ATS Corporation, together with its subsidiaries, provides automation solutions worldwide. The company is also involved in planning, designing, building, commissioning, and servicing automated manufacturing and assembly systems, including automation products and test solutions. In addition, it offers pre-automation services comprising discovery and analysis, concept development, simulation, and total cost of ownership modelling; post automation services, including training, process optimization, preventative maintenance, emergency and on-call support, spare parts, retooling, retrofits, and equipment relocation; and contract manufacturing services, as well as after sales and services. Further, the company provides engineering design, prototyping, process verification, specification writing, software and manufacturing process controls development, standard automation products/platforms, equipment design and build, third-party equipment qualification, procurement and integration, automation system installation, product line commissioning, validation, and documentation services. Additionally, it offers value engineering, supply chain management, and integration and manufacturing capabilities, as well as other automation products and solutions; and software and digital solutions comprising connected factory floor management systems to capture, analyze, and use real time machine performance data to troubleshoot, deliver process and product solutions, prevent equipment downtime, drive operational efficiency, and unlock performance for sustainable production improvements. ATS Corporation serves life sciences, transportation and mobility, consumer products, food and beverage, electronics, nuclear, packaging, warehousing and distribution, and energy markets. The company was formerly known as ATS Automation Tooling Systems Inc. and changed its name to ATS Corporation in November 2022. ATS Corporation was founded in 1978 and is headquartered in Cambridge, Canada.

About Wuhan General Group

Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.